Cited 18 times in
Short-Term Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Obstruction and Diabetic Macular Edema
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김민 | - |
dc.contributor.author | 변석호 | - |
dc.contributor.author | 오현섭 | - |
dc.contributor.author | 권오웅 | - |
dc.date.accessioned | 2014-12-21T16:52:01Z | - |
dc.date.available | 2014-12-21T16:52:01Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 1080-7683 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/96500 | - |
dc.description.abstract | OBJECTIVE: The aim of this study was to identify the short-term effect, safety, and durability of intravitreally injected bevacizumab in patients with macular edema (ME) caused by retinal vein obstruction (RVO) and diabetic macular edema (DME). METHODS: We retrospectively evaluated 39 eyes of 36 patients, 14 with ME caused by RVO and 25 with DME, who received intravitreal bevacizumab (1.25 mg) and were followed up for at least 3 months. Monthly assessments examined safety, best corrected visual acuity with an ETDRS chart (logMAR), and central retinal thickness (CRT) using optical coherence tomography. RESULTS: No significant ocular or systemic side-effects were observed. The follow-up period was 5.4 +/- 1.1 months (mean +/- standard deviation). During follow-up, the mean number of injections was 1.4 +/- 0.5. The baseline mean logMAR was 0.91 +/- 0.51, and the mean CRT was 552.6 +/- 186.7 microm. At 1, 2, and 3 months, the mean logMAR was 0.67 +/- 0.46 (paired t test, P < 0.001), 0.66 +/- 0.46 (P < 0.001), and 0.69 +/- 0.45 (P < 0.001), respectively, and the mean CRT was 323.1 +/- 151.9 mum (P < 0.001), 324.6 +/- 136.9 mum (P < 0.001), and 382.5 +/- 130.4 microm (P < 0.001), respectively. Fourteen (14) of 34 eyes with more than 3 months of follow-up required a second injection at a mean 3.4 +/- 1.0 months after the initial injection. For both ME caused RVO and DME patients, a bevacizumab administration improved logMAR and CRT at each time point through to 6 months, except for logMAR in DME at 1 week (P = 0.081), 5 months (P = 0.130) and 6 months (P = 0.759). CONCLUSIONS: An intravitreal bevacizumab injection for ME caused by RVO and DME was safe and effective for improving visual acuity and reducing CRT. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 387~394 | - |
dc.relation.isPartOf | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angiogenesis Inhibitors/adverse effects | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal/adverse effects | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Diabetic Retinopathy/complications | - |
dc.subject.MESH | Diabetic Retinopathy/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Injections | - |
dc.subject.MESH | Macular Edema/drug therapy* | - |
dc.subject.MESH | Macular Edema/etiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Retina/drug effects | - |
dc.subject.MESH | Retina/pathology | - |
dc.subject.MESH | Retinal Vein Occlusion/complications | - |
dc.subject.MESH | Retinal Vein Occlusion/drug therapy* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Tomography, Optical Coherence | - |
dc.subject.MESH | Vision Tests | - |
dc.subject.MESH | Visual Acuity/drug effects | - |
dc.title | Short-Term Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Obstruction and Diabetic Macular Edema | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | Suk H. Byeon | - |
dc.contributor.googleauthor | Young A. Kwon | - |
dc.contributor.googleauthor | Oh W. Kwon | - |
dc.contributor.googleauthor | Min Kim | - |
dc.contributor.googleauthor | Hyun-Sub Oh | - |
dc.identifier.doi | 10.1089/jop.2007.0012 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00455 | - |
dc.contributor.localId | A01849 | - |
dc.contributor.localId | A02414 | - |
dc.contributor.localId | A00235 | - |
dc.relation.journalcode | J01654 | - |
dc.identifier.eissn | 1557-7732 | - |
dc.identifier.pmid | 17803438 | - |
dc.identifier.url | http://online.liebertpub.com/doi/abs/10.1089/jop.2007.0012 | - |
dc.contributor.alternativeName | Kim, Min | - |
dc.contributor.alternativeName | Byeon, Suk Ho | - |
dc.contributor.alternativeName | Oh, Hyun Sub | - |
dc.contributor.alternativeName | Kwon, Oh Woong | - |
dc.contributor.affiliatedAuthor | Kim, Min | - |
dc.contributor.affiliatedAuthor | Byeon, Suk Ho | - |
dc.contributor.affiliatedAuthor | Oh, Hyun Sub | - |
dc.contributor.affiliatedAuthor | Kwon, Oh Woong | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 23 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 387 | - |
dc.citation.endPage | 394 | - |
dc.identifier.bibliographicCitation | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, Vol.23(4) : 387-394, 2007 | - |
dc.identifier.rimsid | 36120 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.